Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025
Rhea-AI Summary
Burning Rock Biotech (NASDAQ: BNR) will hold its 2025 Annual General Meeting on December 23, 2025 at 10:30 a.m. local time at its Shanghai office: 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai.
The AGM agenda includes ratifying the appointment of Ernst & Young Hua Ming LLP as auditor for the year ending December 31, 2025, re-election of Feng Deng and Licen Lisa Xu as directors, and authorizing directors to take actions to effect those resolutions. The board recommends shareholders and ADS holders vote in favor.
The record date for shareholders entitled to notice is December 1, 2025 (New York time). ADS holders must instruct Citibank, N.A. to vote underlying Class A shares. Burning Rock filed its Form 20-F with audited financials for year ended December 31, 2024.
Positive
- None.
Negative
- None.
GUANGZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 23, 2025 at 10:30 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company’s website, within Investors Relation section, at https://ir.brbiotech.com.
The AGM will be held for the following proposals:
- as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2025 be ratified and that the directors of the Company be authorized to determine the remuneration of the auditor;
- as an ordinary resolution, THAT Feng Deng and Licen Lisa Xu be re-elected as directors of the Company; and
- as an ordinary resolution, THAT each of the directors of the Company be authorized to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.
The board of directors of the Company fully supports these proposals and recommends that shareholders and holders of American depositary shares (“ADSs”) vote in favor of these proposals.
The board of directors of the Company has fixed the close of business on December 1, 2025 (New York time) as the record date for determining the shareholders entitled to receive notice of the AGM or any adjournment or postponement thereof. Holders of record of the Company’s Class A ordinary shares or Class B ordinary shares, each with a par value of US
The board of directors of the Company fully supports the proposed resolutions and recommends that shareholders and holders of ADSs vote in favor of the proposed resolutions.
The Company has filed its annual report on Form 20-F containing the complete audited financial statements and the report of auditors for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the “SEC”), which can be accessed on the Company’s website at https://ir.brbiotech.com, and on SEC’s website at http://www.sec.gov.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
Contact: IR@brbiotech.com
FAQ
When and where is Burning Rock Biotech's (BNR) 2025 Annual General Meeting?
What resolutions will shareholders vote on at Burning Rock (BNR) AGM on December 23, 2025?
Who is eligible to vote at Burning Rock (BNR) AGM and what is the record date?
Where can investors find the AGM notice, proxy form, and Burning Rock (BNR) annual report?
How should ADS holders of Burning Rock (BNR) submit voting instructions for the December 23, 2025 AGM?
